Searched for
INSUGEN
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunityNovo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the a...- Biocon share price slips over 6% after CFO resignsShares of Biocon fell over 6% to Rs 250.3 in Friday's trade on BSE after the firm said that its chief financial officer (CFO), Indranil Sen...
- Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 croreAs part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics wins $90 mn contract from Malaysia to supply human insulinBiocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authori...
- Private equity firm GE Capital pays Rs 125 crore for 7.7% stake in Biocon SyngeneGE Capital, the private equity arm of GE, on Wednesday picked up 7.69% in Syngene, the research services subsidiary of biotech firm Biocon,...
- Biocon posts 4.6% increase in net profit to Rs 89.65 croreBiotechnology firm Biocon's net profits for Q2 of FY13 was 89.65 crore, an increase of 4.6% when compared to the same period last year.
- GE capital picks up 7.69% in Biocon's Syngene for Rs 125 croreThe total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.
- Biocon joins hands with US co Amylin for diabetes drugBiocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals.
- Biocon picks up 70% in German pharma co AxiCorp for e30 mnThe deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.
- Biocon in talks with Bayer for drug developmentTwo pharma cos may sign pact involving co-development of new biotech drugs & research services.
- Biocon Q4 net up 27% to Rs 61 crBangalore-based Biocon has posted a consolidated net profit of Rs 61 crore for the fourth quarter ended March 31, 2007, up 27% from Rs 48 c...
- Clinical trials for oral insulin to enter phase two: BioconAfter the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.
- Biocon signs agreement with BayerBiotech major Biocon Limited announced on Wednesday a licensing agreement with multinational healthcare corporation Bayer HealthCare (BHC) ...
Load More
